Related Experiment Videos
Clinical impact of hyperprolactinaemia
1Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City 52242, USA.
Bailliere'S Clinical Endocrinology and Metabolism
|April 1, 1995
Summary
Prolactinomas, pituitary tumors causing reproductive issues, often resolve spontaneously or with dopamine agonist treatment. While bone density improves post-treatment, it may not fully normalize, and long-term estrogen therapy safety is under investigation.
Area of Science:
- Endocrinology
- Oncology
- Reproductive Medicine
Background:
- Prolactinomas are benign pituitary tumors impacting reproductive health in both sexes.
- Microadenomas often have a benign course, potentially resolving without intervention.
- Hyperprolactinemia can lead to hypogonadism and decreased bone mineral density.
Purpose of the Study:
- To review the clinical course and treatment of prolactinomas.
- To assess the impact of hyperprolactinemia on bone health and the effects of treatment.
- To discuss management strategies for hyperprolactinemia, including fertility restoration and macroadenoma treatment.
Main Methods:
- Literature review of prolactinoma management.
- Analysis of treatment outcomes for hyperprolactinemia.
- Evaluation of bone mineral density changes in relation to hyperprolactinemia and its treatment.
Main Results:
- Dopamine agonists are the primary treatment, normalizing prolactin levels and restoring menses in most patients.
- Hyperprolactinemia-induced hypogonadism is linked to reduced spinal bone mineral content.
- Bone mass improves with treatment but may not reach normalization levels.
Conclusions:
- Dopamine agonist therapy is effective for prolactinomas, regardless of tumor size.
- Further research is needed on the long-term safety of estrogen therapy in women with hyperprolactinemic amenorrhea not seeking fertility.
- Management should focus on restoring fertility and addressing macroadenomas when present.